AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ostrosky-Zeichner, L.
Right arrow Articles by Rex, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ostrosky-Zeichner, L.
Right arrow Articles by Rex, J. H.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2781-2786, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2781-2786.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Differential Antifungal Activity of Isomeric Forms of Nystatin

Luis Ostrosky-Zeichner,1,* Scott Bazemore,2 Victor L. Paetznick,1 Jose R. Rodriguez,1 Enuo Chen,1 Tom Wallace,2 Paul Cossum,2 and John H. Rex1

Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine, and Center for the Study of Emerging and Re-emerging Pathogens, University of Texas Houston Medical School, Houston, Texas 77030,1 and Aronex Pharmaceuticals, The Woodlands, Texas 773812

Received 1 February 2001/Returned for modification 31 May 2001/Accepted 19 July 2001

When nystatin is placed in RPMI and other biological fluids, there is loss of pure nystatin, with the development of two distinguishable chromatographic peaks, 1 and 2. Peak 1 appears identical to commercially prepared nystatin. By nuclear magnetic resonance (NMR) and mass spectral analysis, peak 2 appears to be an isomer of peak 1. The isomers are quantitatively and fully interconvertible. Formation of peak 2 is accelerated at a pH of >7.0 and ultimately reaches a near 55:45 (peak 1/peak 2 ratio) mixture. We sought to determine the relative activities of peaks 1 and 2 against Candida spp. Peak 2 consistently showed higher MICs when it was the predominant form during the experiment. Time-kill analyses showed that peak 2 required >= 8× the concentration of peak 1 to produce a modest and delayed killing effect, which was never of the same magnitude as that produced by peak 1. In both types of assays, the activity of peak 2 corresponded with intra-assay formation of peak 1. Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1.


* Corresponding author. Mailing address: Division of Infectious Diseases, 6431 Fannin, JFB 1.728, Houston, TX 77030. Phone: (713) 500-5388. Fax: (713) 500-5495. E-mail: Luis.Ostrosky-Zeichner{at}uth.tmc.edu.


Antimicrobial Agents and Chemotherapy, October 2001, p. 2781-2786, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2781-2786.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.